Hyperzincuria and hypozincemia in patients treated with cisplatin.
The effect of cis-diamminedichloroplatinum (DDP) on plasma and urinary zinc was studied in fifteen patients with squamous cell carcinoma. A decrease in plasma zinc accompanied by an increase in urinary zinc excretion was observed. Pretreatment plasma or urinary zinc did not correlate with tumor size or site, nor was there a correlation between changes in these measurements and a response to therapy. The enhanced excretion of urinary zinc may be related to a decrease in amino acid resorption in the proximal tubule. It is concluded that DDP administration may result in hyperzincuria and could potentially precipitate a symptomatic zinc deficiency state.
Sweeney
J D
JD
Division of Oncology, Veterans Administration Medical Center, Buffalo, New York.
Ziegler
P
P
Pruet
C
C
Spaulding
M B
MB
D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000188:drug therapy / Q000652:urine; D002940:Circadian Rhythm; D002945:Cisplatin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D015032:Zinc / Q000097:blood* / Q000652:urine*
D015032:Zinc; D002945:Cisplatin